IL2 Treatment for Cancer: From Biology to Gene Therapy
Author Information
Author(s): R. Foa, A. Guarini, B. Gansbacher
Primary Institution: Dipartimento di Scienze Biomediche e Oncologia Umana, Torino, Italy; Memorial Sloan-Kettering Cancer Center, New York, USA
Hypothesis
Can IL2-based immunotherapy improve cancer treatment outcomes?
Conclusion
IL2 gene therapy shows promise in reducing tumorigenicity and enhancing immune responses in cancer patients.
Supporting Evidence
- IL2 has shown objective responses in patients with advanced cancer.
- Complete or partial responses were observed in about 20% of patients with metastatic renal cell cancer and melanoma.
- IL2 gene transfer into tumor cells has been successful in animal models and human tumor cells.
Takeaway
Scientists are exploring a new way to treat cancer by using a special protein called IL2 to help the body's immune system fight tumors better.
Methodology
The review discusses clinical findings and biological rationale for IL2-based immunotherapy in cancer management.
Limitations
The clinical use of IL2 has been limited by toxicity and unpredictable responses.
Participant Demographics
The review includes findings from studies on patients with advanced cancer, particularly those with renal cell carcinoma, melanoma, and acute myeloid leukemia.
Want to read the original?
Access the complete publication on the publisher's website